Document text
Principal Investigator: RONALD N HARTY
Organization: FOX CHASE CHEMICAL DIVERSITY CENTER, INC
Fiscal Year: 2023
Award: $292,428
Funding agency: National Institute of Allergy and Infectious Diseases
The ultimate goal of this Phase I application is to discover and develop host-oriented small molecule compounds
targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 is a novel
coronavirus driving the current global pandemic of severe respiratory syndrome in humans. Antiviral therapeutics
are urgently needed to combat infection by SARS-CoV-2 and new variants that are continuing to emerge. We
have discovered several chemical series that target modular interactions between specific host proteins
containing WW-domains (e.g. Nedd4) and viral proteins containing PPxY motifs (e.g. Ebola VP40). Notably,
emerging RNA virus pathogens such as Ebola, Marburg, Lassa, and rabies viruses all encode PPxY motifs that
recruit host WW-domain containing proteins to facilitate efficient virus egress, spread, and transmission.
Interestingly, the surface-exposed Spike glycoprotein (S) of SARS-CoV-2 also has a putative WW-domain
binding motif (25PPAY28), that is not present in the S protein of SARS-CoV-1 or more attenuated coronavirus
strains. The acquisition of this PPAY motif in the major surface protein of SARS-CoV-2 virions raises the
intriguing possibility that it may contribute to the unique pathogenicity and/or transmission of SARS-CoV-2 via
interactions with specific host WW-domain bearing proteins. In our ongoing studies on filoviruses and
arenaviruses, we have used extensive SAR to identify a lead compound series capable of blocking egress and
spread of live EBOV, MARV, and LAFV in cell culture, as well as blocking disease progression in vivo in a live
MARV challenge model. Here, we hypothesize that “informed” SAR analyses of our in-hand PPxY/WW-domain
inhibitors (e.g. lead candidate FC-10696) will lead to the discovery of analogs capable of blocking egress and
disease progression of SARS-CoV-2, as well as related PPxY-containing variants that may emerge in the future.
In support of our hypothesis, we present strong preliminary data showing that the PPxY motif within the S protein
of SARS-CoV-2 virus can interact with host WW-domain containing proteins that are known to promote egress
and spread of EBOV, MARV, and LAFV. Moreover, our current lead candidate PPxY budding inhibitors show
activity in blocking egress of live SARS-CoV-2 virus infection in human lung epithelial cells. In this Phase I
proposal, we will identify and evaluate host-oriented inhibitors as potential therapeutics for SARS-CoV-2 and
related coronaviruses by combining the pharmaceutical and medicinal chemistry expertise of the scientists at
the Fox Chase Chemical Diversity Center, Inc. (FCCDC) with the expertise and experience of the Harty Lab at
the University of Pennsylvania in the experimental aspects of virus-host interactions and antiviral therapy, and
the lab of Olena Shtanko at Texas Biomedical Research Institute for evaluating compounds against live viruses
under BSL-3 conditions. The three aims are (1) lead finding and optimization medicinal chemistry including
ADME profiling, (2) evaluation for the ability to specifically inhibit egress of SARS-CoV-2 VLPs and PPxY-
mediated S-host protein interactions, and (3) in vitro and in vivo analyses against authentic SARS-CoV-2 virus.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><ACE2><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Arenaviridae><Arenavirus><Arenavirus group><Assay><Attenuated><Automobile Driving><Binding><Binding Proteins><Bioassay><Biologic Assays><Biological Assay><Biomedical Research><COVID-19 S protein><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 therapeutics><COVID-19 transmission><COVID-19 virus><COVID-19 virus infection><COVID-19 virus transmission><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 therapeutics><COVID19 virus><Cell Culture Techniques><Chemicals><CoV emergence><CoV-2><CoV2><Coronaviridae><Coronavirus><Data><Development><Disease Progression><Disease model><EBOV><Ebola><Ebola virus><Ebola-like Viruses><Epithelial Cells><Evaluation><Filoviridae><Filovirus><Frankfurt-Marburg Syndrome Virus><Future><Goals><Hand><Human><In Vitro><Investigation><Lassa fever virus><Lassa virus><Lead><Ligand Binding Protein><Ligand Binding Protein Gene><Lung><Lung Respiratory System><Marburg><Marburg virus><Marburg-like Viruses><Marburgvirus><Mediating><Medicinal Chemistry><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Metabolic><Mice><Mice Mammals><Microsomes><Modeling><Modern Man><Molecular Interaction><Murine><Mus><Oral><Pathogenicity><Pb element><Pennsylvania><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Phase><Plasma Proteins><Process><Property><Protein Binding><Proteins><RNA Viruses><Rabies virus><Research Institute><SARS Virus><SARS corona virus><SARS corona virus 2><SARS coronavirus><SARS-Associated Coronavirus><SARS-CO-V2><SARS-COVID-2><SARS-CoV><SARS-CoV-1><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 therapeutics><SARS-CoV-2 transmission><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-Related Coronavirus><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 therapeutics><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><STTR><Scientist><Series><Severe Acute Respiratory Coronavirus><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 therapeutics><Severe acute respiratory syndrome related corona virus 2><Small Business Technology Transfer Research><Solubility><Surface><Surface Proteins><Syndrome><Texas><Toxic effect><Toxicities><Transmission><Universities><Variant><Variation><Viral><Viral Activity><Viral Diseases><Viral Function><Viral Gene Products><Viral Gene Proteins><Viral Physiology><Viral Proteins><Virion><Virus><Virus Diseases><Virus Particle><Wuhan coronavirus><analog><angiotensin converting enzyme 2><angiotensin converting enzyme II><anti-viral agents><anti-viral compound><anti-viral development><anti-viral drug development><anti-viral drugs><anti-viral efficacy><anti-viral medication><anti-viral therapeutic><anti-viral therapeutic development><anti-viral therapy><anti-viral therapy development><anti-virals><antiviral compound><antiviral development><antiviral drug development><antiviral efficacy><antiviral medication><antiviral therapeutic><antiviral therapeutic development><antiviral therapy development><attenuate><attenuates><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><bound protein><cell culture><cell cultures><combat><corona virus><corona virus emergence><coronavirus disease 2019 S protein><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 therapeutics><coronavirus disease 2019 transmission><coronavirus disease 2019 virus><coronavirus disease 2019 virus transmission><coronavirus disease-19 virus><coronavirus emergence><developing anti-viral agent><developing anti-viral drug><developing anti-viral therapeutic><developing anti-viral therapy><developing antiviral agent><developing antiviral drug><developing antiviral therapeutic><developing antiviral therapy><developmental><disorder model><driving><ebolavirus><emergent CoV><emergent corona virus><emergent coronavirus><emerging CoV><emerging corona virus><emerging coronavirus><experience><gastrointestinal><hCoV19><hands><heavy metal Pb><heavy metal lead><in vivo><in vivo evaluation><in vivo testing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><inhibitor><lead candidate><lead optimization><meeting><meetings><mouse model><murine model><nCoV><nCoV2><new CoV><new corona virus><new coronavirus><novel CoV><novel corona virus><novel coronavirus><pandemic><pandemic disease><pathogenic virus><pulmonary><recruit><respiratory><scale up><severe acute respiratory syndrome coronavirus 2 transmission><severe acute respiratory syndrome-CoV><small molecule><therapeutic target><therapeutics against COVID-19><therapeutics against COVID19><therapeutics against SARS-CoV-2><therapeutics against SARS-coronavirus-2><therapeutics against Severe acute respiratory syndrome coronavirus 2><therapeutics against coronavirus disease 2019><therapeutics for novel coronavirus><transmission process><transmitted COVID-19><transmitted SARS-CoV-2><transmitted coronavirus disease 2019><transmitted severe acute respiratory syndrome coronavirus 2><viral infection><viral infectious disease treatment><viral pathogen><virus host interaction><virus infection><virus pathogen><virus protein><virus-induced disease>